Literature DB >> 33489897

Development and Validation of a Radiomic-Based Model for Prediction of Intrahepatic Cholangiocarcinoma in Patients With Intrahepatic Lithiasis Complicated by Imagologically Diagnosed Mass.

Beihui Xue1, Sunjie Wu1, Minghua Zheng2, Huanchang Jiang3, Jun Chen3, Zhenghao Jiang3, Tian Tian3, Yifan Tu3, Huanhu Zhao4, Xian Shen5, Kuvaneshan Ramen6, Xiuling Wu7, Qiyu Zhang8, Qiqiang Zeng5, Xiangwu Zheng1.   

Abstract

BACKGROUND: This study was conducted with the intent to develop and validate a radiomic model capable of predicting intrahepatic cholangiocarcinoma (ICC) in patients with intrahepatic lithiasis (IHL) complicated by imagologically diagnosed mass (IM).
METHODS: A radiomic model was developed in a training cohort of 96 patients with IHL-IM from January 2005 to July 2019. Radiomic characteristics were obtained from arterial-phase computed tomography (CT) scans. The radiomic score (rad-score), based on radiomic features, was built by logistic regression after using the least absolute shrinkage and selection operator (LASSO) method. The rad-score and other independent predictors were incorporated into a novel comprehensive model. The performance of the Model was determined by its discrimination, calibration, and clinical usefulness. This model was externally validated in 35 consecutive patients.
RESULTS: The rad-score was able to discriminate ICC from IHL in both the training group (AUC 0.829, sensitivity 0.868, specificity 0.635, and accuracy 0.723) and the validation group (AUC 0.879, sensitivity 0.824, specificity 0.778, and accuracy 0.800). Furthermore, the comprehensive model that combined rad-score and clinical features was great in predicting IHL-ICC (AUC 0.902, sensitivity 0.771, specificity 0.923, and accuracy 0.862).
CONCLUSIONS: The radiomic-based model holds promise as a novel and accurate tool for predicting IHL-ICC, which can identify lesions in IHL timely for hepatectomy or avoid unnecessary surgical resection.
Copyright © 2021 Xue, Wu, Zheng, Jiang, Chen, Jiang, Tian, Tu, Zhao, Shen, Ramen, Wu, Zhang, Zeng and Zheng.

Entities:  

Keywords:  intrahepatic cholangiocarcinoma; intrahepatic lithiasis; nomogram; radiomics; risk factors

Year:  2021        PMID: 33489897      PMCID: PMC7817533          DOI: 10.3389/fonc.2020.598253

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  23 in total

1.  Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.

Authors:  F Donato; U Gelatti; A Tagger; M Favret; M L Ribero; F Callea; C Martelli; A Savio; P Trevisi; G Nardi
Journal:  Cancer Causes Control       Date:  2001-12       Impact factor: 2.506

2.  LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity.

Authors:  Christophe Nioche; Fanny Orlhac; Sarah Boughdad; Sylvain Reuzé; Jessica Goya-Outi; Charlotte Robert; Claire Pellot-Barakat; Michael Soussan; Frédérique Frouin; Irène Buvat
Journal:  Cancer Res       Date:  2018-06-29       Impact factor: 12.701

3.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

4.  Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years.

Authors:  Yutaka Suzuki; Toshiyuki Mori; Masaaki Yokoyama; Tetsuya Nakazato; Nobutsugu Abe; Yasuni Nakanuma; Hirohito Tsubouchi; Masanori Sugiyama
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-05-14       Impact factor: 7.027

5.  Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.

Authors:  Y-T Kim; J S Byun; J Kim; Y H Jang; W J Lee; J K Ryu; S W Kim; Y B Yoon; C Y Kim
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb

6.  Hepatolithiasis-associated cholangiocarcinoma: results from a multi-institutional national database on a case series of 23 patients.

Authors:  A Guglielmi; A Ruzzenente; A Valdegamberi; F Bagante; S Conci; A D Pinna; G Ercolani; F Giuliante; L Capussotti; L Aldrighetti; C Iacono
Journal:  Eur J Surg Oncol       Date:  2013-12-18       Impact factor: 4.424

7.  Biliary Tract Cancer at CT: A Radiomics-based Model to Predict Lymph Node Metastasis and Survival Outcomes.

Authors:  Gu-Wei Ji; Yu-Dong Zhang; Hui Zhang; Fei-Peng Zhu; Ke Wang; Yong-Xiang Xia; Yao-Dong Zhang; Wang-Jie Jiang; Xiang-Cheng Li; Xue-Hao Wang
Journal:  Radiology       Date:  2018-10-16       Impact factor: 11.105

8.  Intrahepatic stones associated with cholangiocarcinoma.

Authors:  M F Chen; Y Y Jan; C S Wang; L B Jeng; T L Hwang; S C Chen
Journal:  Am J Gastroenterol       Date:  1989-04       Impact factor: 10.864

9.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

10.  Cholangiocarcinoma Risk as Long-term Outcome After Hepatic Resection in the Hepatolithiasis Patients.

Authors:  Hyo Jung Kim; Jae Seon Kim; Sang Jun Suh; Beom Jae Lee; Jong-Jae Park; Hong Sik Lee; Chang Duck Kim; Young-Tae Bak
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

View more
  8 in total

Review 1.  Radiomics of Biliary Tumors: A Systematic Review of Current Evidence.

Authors:  Francesco Fiz; Visala S Jayakody Arachchige; Matteo Gionso; Ilaria Pecorella; Apoorva Selvam; Dakota Russell Wheeler; Martina Sollini; Luca Viganò
Journal:  Diagnostics (Basel)       Date:  2022-03-28

2.  Maximum Standardized Uptake Value of 18F-deoxyglucose PET Imaging Increases the Effectiveness of CT Radiomics in Differentiating Benign and Malignant Pulmonary Ground-Glass Nodules.

Authors:  Rong Niu; Jianxiong Gao; Xiaoliang Shao; Jianfeng Wang; Zhenxing Jiang; Yunmei Shi; Feifei Zhang; Yuetao Wang; Xiaonan Shao
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

3.  A2M is a potential core gene in intrahepatic cholangiocarcinoma.

Authors:  Guanran Zhang; Xuyue Liu; Zhengyang Sun; Xiaoning Feng; Haiyan Wang; Jing Hao; Xiaoli Zhang
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

4.  Development and Validation of a Radiomics Model Based on 18F-FDG PET of Primary Gastric Cancer for Predicting Peritoneal Metastasis.

Authors:  Beihui Xue; Jia Jiang; Lei Chen; Sunjie Wu; Xuan Zheng; Xiangwu Zheng; Kun Tang
Journal:  Front Oncol       Date:  2021-10-26       Impact factor: 6.244

5.  An update on radiomics techniques in primary liver cancers.

Authors:  Vincenza Granata; Roberta Fusco; Sergio Venazio Setola; Igino Simonetti; Diletta Cozzi; Giulia Grazzini; Francesca Grassi; Andrea Belli; Vittorio Miele; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2022-03-04       Impact factor: 2.965

6.  A Novel Clinical-Radiomics Model Based on Sarcopenia and Radiomics for Predicting the Prognosis of Intrahepatic Cholangiocarcinoma After Radical Hepatectomy.

Authors:  Liming Deng; Bo Chen; Chenyi Zhan; Haitao Yu; Jiuyi Zheng; Wenming Bao; Tuo Deng; Chongming Zheng; Lijun Wu; Yunjun Yang; Zhengping Yu; Yi Wang; Gang Chen
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

7.  Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma.

Authors:  Vincenza Granata; Roberta Fusco; Andrea Belli; Valentina Borzillo; Pierpaolo Palumbo; Federico Bruno; Roberta Grassi; Alessandro Ottaiano; Guglielmo Nasti; Vincenzo Pilone; Antonella Petrillo; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2022-03-28       Impact factor: 2.965

8.  Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment.

Authors:  Lukas Müller; Aline Mähringer-Kunz; Simon Johannes Gairing; Friedrich Foerster; Arndt Weinmann; Fabian Bartsch; Lisa-Katharina Heuft; Janine Baumgart; Christoph Düber; Felix Hahn; Roman Kloeckner
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.